Tirzepatide
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis, Overweight or Obesity
Trial Timeline
Mar 6, 2025 → Nov 1, 2027
NCT ID
NCT06864026About Tirzepatide
Tirzepatide is a approved stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864026. Target conditions include Psoriatic Arthritis, Overweight or Obesity.
What happened to similar drugs?
9 of 20 similar drugs in Psoriatic Arthritis were approved
Approved (9) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07438444 | Approved | Recruiting |
| NCT07299084 | Phase 1 | Recruiting |
| NCT07247084 | Approved | Recruiting |
| NCT06857942 | Approved | Recruiting |
| NCT06864026 | Approved | Recruiting |
| NCT06635057 | Approved | Active |
| NCT05912621 | Phase 2 | Recruiting |
| NCT05978713 | Phase 1 | Completed |
| NCT05810597 | Phase 1 | Completed |
| NCT05706506 | Approved | Completed |
| NCT04844918 | Phase 3 | Completed |
| NCT04847557 | Phase 3 | Completed |
| NCT04657003 | Phase 3 | Completed |
| NCT04660643 | Phase 3 | Completed |
| NCT04657016 | Phase 3 | Completed |
| NCT04050670 | Phase 1 | Completed |
| NCT04004988 | Phase 1 | Completed |
| NCT03940742 | Phase 1 | Completed |
| NCT03482024 | Phase 1 | Completed |
Competing Products
20 competing products in Psoriatic Arthritis